Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

BACKGROUND: Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selective peroxisome proliferator-activated receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097867/
https://www.ncbi.nlm.nih.gov/pubmed/33947390
http://dx.doi.org/10.1186/s12933-021-01291-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097867/
https://www.ncbi.nlm.nih.gov/pubmed/33947390
http://dx.doi.org/10.1186/s12933-021-01291-w

Ejemplares similares